GLP-1 and GIP Agonists for Neurodegeneration

📖 Wiki Page

therapeutic935 wordssynced 2026-04-02

GLP-1 and GIP Dual Agonists in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 and GIP Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Insulin Signaling</td>
<td>Improve brain insulin sensitivity and glucose metabolism</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Reduce microglial activation and pro-inflammatory cytokines</td>
</tr>
<tr>
<td class="label">Synaptic Plasticity</td>
<td>Enhance [LTP](/mechanisms/long-term-potentiation), improve dendritic spine density</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Promote hippocampal neurogenesis in adult brain</td>
</tr>
<tr>
<td class="label">Mitochondrial Function</td>
<td>Improve mitochondrial biogenesis and reduce oxidative stress</td>
</tr>
<tr>
<td class="label">Protein Clearance</td>
<td>Enhance [autophagy](/entities/autophagy) and reduce protein aggregate accumulation</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Activate PI3K/Akt pathway to prevent neuronal death</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT04777396</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04777409</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04269642</td>
<td>Liraglutide</td>
</tr>
<tr>
<td class="label">NCT02953665</td>
<td>Exenatide</t

...

GLP-1 and GIP Dual Agonists in Neurodegeneration

Introduction

Glp 1 And Gip Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists represent a breakthrough therapeutic approach for neurodegenerative diseases. Originally developed for type 2 diabetes, these incretin hormones have shown remarkable neuroprotective properties in preclinical and clinical studies. Dual GLP-1/GIP agonists (tirzepatide) and triple agonists are now being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@athauda2017]

Molecular Mechanism

GLP-1 and GIP agonists work through multiple neuroprotective pathways: [@femminella2021]

Key Drug Candidates

Tirzepatide (Mounjaro)

Mechanism: Dual GLP-1 and GIP receptor agonist
Clinical Status: FDA-approved for type 2 diabetes; Phase II for AD/PD
Evidence: Superior neuroprotection vs. GLP-1 alone in models

Semaglutide (Ozempic/Wegovy)

Mechanism: Long-acting [GLP-1 receptor](/entities/glp1-receptor) agonist
Clinical Status: FDA-approved for diabetes/weight loss; Phase III for AD (EVOKE/EVOKE+)
Evidence: Reduces [Aβ](/proteins/amyloid-beta), improves cognition in AD models

Liraglutide (Victoza)

Mechanism: GLP-1 receptor agonist (daily injection)
Clinical Status: Approved for diabetes; Phase II completed for AD
Evidence: Improved memory in MCI patients (ELAD trial)

Exenatide (Bydureon)

Mechanism: GLP-1 receptor agonist (exendin-4 analog)
Clinical Status: Approved for diabetes; Phase II for PD (completed)
Evidence: Improved motor symptoms in PD patients

DA-CH5 (Dual Amylin/GLP-1 Agonist)

Mechanism: Novel dual amylin and GLP-1 receptor agonist
Clinical Status: Preclinical development
Evidence: Enhanced neuroprotection vs. single agonists

Disease-Specific Applications

Alzheimer's Disease

Improves brain insulin sensitivity (Type 3 diabetes hypothesis)
Reduces [Aβ](/proteins/amyloid-beta) plaque formation and [tau](/proteins/tau) phosphorylation
Enhances synaptic plasticity and memory function
EVOKE/EVOKE+ Phase III trials ongoing with semaglutide

Parkinson's Disease

Protects dopaminergic [neurons](/entities/neurons) from degeneration
Improves motor function in PD patients
Reduces neuroinflammation in substantia nigra
Exenatide trial showed sustained motor improvement

Amyotrophic Lateral Sclerosis

Modulates microglial activation
Improves metabolic function in motor neurons
Extends survival in preclinical models
Clinical trials planned

Vascular Cognitive Impairment

Improves cerebral blood flow
Reduces vascular inflammation
Enhances cognitive function

Clinical Trials

Comparison of Incretin Therapies

Research Directions

Current research focuses on:

Brain-penetrant incretin analogs with enhanced CNS delivery
Triple agonists (GLP-1/GIP/amylin) for enhanced neuroprotection
Biomarkers to identify responders (brain insulin sensitivity)
Combination with disease-modifying therapies

External Links

[ClinicalTrials.gov - GLP-1 Neurodegeneration](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=GLP-1)
[EVOKE Phase III Trial Information](https://clinicaltrials.gov/ct2/show/NCT04777396)
[Incretin Therapy Review - Nature](https://pubmed.ncbi.nlm.nih.gov/?term=GLP-1+agonist+Alzheimer+disease)

Background

The study of Glp 1 And Gip Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Unknown, Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects. Neuropharmacology. 2020;169:107809 (2020)](https://pubmed.ncbi.nlm.nih.gov/32092367/)

[Athauda D, et al, Exenatide once weekly versus placebo in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28754928/)

[Femminella GD, et al, GLP-1 receptor agonists in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34253928/)

[Salameh JI, et al, Tirzepatide neuroprotection in models of Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36863728/)

[Gejl M, et al, Liraglutide improves cognition in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34568923/)

[Malhotra G, et al, GLP-1 agonists as disease-modifying therapy for Parkinson's (2020)](https://pubmed.ncbi.nlm.nih.gov/32657034/)

[Li Y, et al, Incretin-based therapies and Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33559352/)

[Park JS, et al, GIP receptor agonism enhances GLP-1 neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35926491/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄

📖 View canonical wiki page →

GLP-1 and GIP Agonists for Neurodegeneration

GLP-1 and GIP Dual Agonists in Neurodegeneration

GLP-1 and GIP Dual Agonists in Neurodegeneration

Introduction

Overview

Molecular Mechanism

Key Drug Candidates

Tirzepatide (Mounjaro)

Semaglutide (Ozempic/Wegovy)

Liraglutide (Victoza)

Exenatide (Bydureon)

DA-CH5 (Dual Amylin/GLP-1 Agonist)

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Vascular Cognitive Impairment

Clinical Trials

Comparison of Incretin Therapies

Research Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses